How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

806 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. (PubMed)

Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. To evaluate the effects of galantamine withdrawal, and compare this with uninterrupted therapy, two 6-week double-blind withdrawal studies (Studies 1 and 2) were performed. These enrolled individuals who had completed one of two 3- or 5-month randomized clinical trials (parent trials) involving patients with mild to moderate Alzheimer's disease (AD). In Study 1 (GAL (...) -USA-11; n'723), patients continuously treated with galantamine 16 mg/day exhibited a mean (± standard error [SE]) improvement in 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale score of 1.8 (± 0.46) points at Week 6 compared with the parent trial baseline, (p < 0.001 vs placebo; observed cases analysis). Over the same period, patients switched from galantamine to placebo and those who had received continuous placebo, exhibited mean (± SE) deteriorations of 0.7 (± 0.49

2011 Current Alzheimer research Controlled trial quality: uncertain

102. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. (PubMed)

Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. In Alzheimer's disease (AD), it is important to consider long-term effects, not only in patients receiving treatment, but also in subjects in whom therapy has been discontinued. The present analysis evaluates the long-term effects of galantamine on cognitive function in AD in terms of Mini-Mental State Examination (MMSE) scores for up to 7 years, using both clinical (...) data and epidemiological modeling. Consideration is given not only to patients continuing to receive galantamine therapy, but also to those who stop this treatment. In a retrospective review of medical notes, re-contacted study investigators obtained data from 258 patients originally recruited into three previously described randomized clinical trials involving galantamine: two placebo-controlled trials in mild-to-moderate AD (of 3 and 6 months' duration, followed by open-label extensions

Full Text available with Trip Pro

2011 Journal of Alzheimer's disease : JAD Controlled trial quality: uncertain

103. Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology. (PubMed)

Development and in vivo evaluation of novel monolithic controlled release compositions of galantamine hydrobromide as against reservoir technology. The objective of this study is to develop and in vivo evaluation of novel monolithic matrix mini tablets approach to control the release of galantamine hydrobromide (GAH) in comparison with desired release profile to the Innovator formulation Razadyne(®) ER capsules. The direct compression method was employed for preparation of matrix mini tablets

2011 Pharmaceutical development and technology Controlled trial quality: uncertain

104. The effect of galantamine on the blood pressure of the rat. (PubMed)

The effect of galantamine on the blood pressure of the rat. 4380412 1966 11 28 2018 11 13 0366-0826 26 2 1966 Feb British journal of pharmacology and chemotherapy Br J Pharmacol Chemother The effect of galantamine on the blood pressure of the rat. 295-301 Chrusciel M M Varagić V V eng Comparative Study Journal Article England Br J Pharmacol Chemother 0154627 0366-0826 0 Ganglionic Blockers 0 Parasympatholytics 0 Sympatholytics 0D3Q044KCA Galantamine IM Adrenalectomy Animals Blood Pressure drug (...) effects Female Galantamine pharmacology Ganglionic Blockers pharmacology Male Parasympatholytics pharmacology Rats Sympatholytics pharmacology 1966 2 1 1966 2 1 0 1 1966 2 1 0 0 ppublish 4380412 PMC1510659 J Physiol. 1948 Mar 15;107(2):162-4 16991795 Br J Pharmacol Chemother. 1964 Aug;23:34-42 14206267 J Physiol. 1953 Jan;119(1):43-57 13035716 Br J Pharmacol Chemother. 1964 Aug;23:80-9 14206271 Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1957;230(5):448-56 13526758 J Pharmacol Exp Ther. 1962 Jan

Full Text available with Trip Pro

1966 British journal of pharmacology and chemotherapy

105. Galantamine in the Treatment of Minor Depression With Mild to Moderate Alzheimer's Dementia in an Elderly Woman (PubMed)

Galantamine in the Treatment of Minor Depression With Mild to Moderate Alzheimer's Dementia in an Elderly Woman 20944777 2012 08 23 2018 11 13 1555-211X 12 3 2010 Primary care companion to the Journal of clinical psychiatry Prim Care Companion J Clin Psychiatry Galantamine in the treatment of minor depression with mild to moderate Alzheimer's dementia in an elderly woman. 10.4088/PCC.09l00905gry PCC.09l00905 Alagiakrishnan Kannayiram K Department of Medicine, Division of Geriatric Medicine

Full Text available with Trip Pro

2010 Primary Care Companion to the Journal of Clinical Psychiatry

106. The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease

The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01054976 Recruitment Status : Completed First Posted : January 22, 2010 Results First Posted : December 24, 2012 Last Update Posted : December 24

2010 Clinical Trials

107. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. (PubMed)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer's disease (AD). Except for predicted differences in (C(max)) and t(max), comparable doses of once daily galantamine-ER and regular, immediate release galantamine, (galantamine-IR), are pharmacologically equivalent (...) . A 24-week randomized, double-blind, placebo-and active-controlled, multicenter phase III trial, which compared galantamine-IR, galantamine-ER and placebo in subjects with mild to moderate AD (mini-mental state examination [MMSE] score range, 10 to 24) showed that both formulations of galantamine were significantly better than placebo in terms of cognition, although not with regard to global change. There was no difference in drug-related adverse events between galantamine-ER and galantamine-IR

Full Text available with Trip Pro

2010 Clinical interventions in aging

108. Effects of galantamine on beta-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells. (PubMed)

Effects of galantamine on beta-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells. Galantamine (Gal) is an acetylcholinesterase inhibitor and used to treat the symptoms of Alzheimer's disease (AD). Recent studies show that Gal may affect amyloid precursor protein (APP) metabolism and increase release of secretory APPα (sAPPα). However the effect of Gal on amyloid-β peptide (Aβ) release and β-site cleaving enzyme 1 (BACE1) expression

2010 Experimental Gerontology

109. The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2010 Clinical Trials

110. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01190761 Recruitment Status : Completed

2010 Clinical Trials

111. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01190748 Recruitment Status

2010 Clinical Trials

112. Galantamine Treatment for Nonfluent Aphasia in Stroke Patients

Galantamine Treatment for Nonfluent Aphasia in Stroke Patients Galantamine Treatment for Nonfluent Aphasia in Stroke Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Galantamine Treatment (...) by: University of North Carolina, Chapel Hill Study Details Study Description Go to Brief Summary: Cognitive impairment after stroke is common and has a major effect on morbidity and quality of life. Acetylcholinesterase inhibitors have demonstrated benefit in vascular dementia, but efficacy in treating more circumscribed cognitive deficits following stroke, such as aphasia, has not been systematically investigated. This study evaluated the efficacy of Galantamine (Reminyl) in subjects with chronic, stable

2010 Clinical Trials

113. Effects of Galantamine on Cognition

Effects of Galantamine on Cognition Effects of Galantamine on Cognition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects of Galantamine on Cognition The safety and scientific validity of this study (...) Description Go to Brief Summary: Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier. Such cognitive impairments and negative symptoms but much milder are also observed in high-risk groups (such as relatives of schizophrenia patients), who may or may not develop the full blown psychotic disorder. Our study plans to recruit such non-ill subjects to test the effects of galantamine

2010 Clinical Trials

114. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. (PubMed)

The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. A minimum 4-point change at 6 months on the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) is deemed clinically important, but this cut-point has been little studied in relation to clinical meaningfulness. In an investigator-initiated, clinical trial of galantamine, we investigated the extent to which a 4-point change classifies goal attainment by individual (...) patients.Secondary analysis of the video imaging synthesis of treating Alzheimer's disease (VISTA) study: a 4-month, multi-centre, parallel-group, double-blind, placebo-controlled, trial of galantamine in 130 mild-moderate Alzheimer's disease patients (4-month open-label follow-up). ADAS-cog responses at 6 months were compared with outcomes on three clinical measures: clinician's interview based impression of change-plus caregiver input (CIBIC+), patient/carer-goal attainment scaling (PGAS) and clinician-GAS

Full Text available with Trip Pro

2010 International Journal of Geriatric Psychiatry Controlled trial quality: predicted high

115. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]. (PubMed)

[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]. Since January 2008 in The Netherlands, two cholinesterase inhibitors, oral galantamine and rivastigmine transdermal patch, are registered as a one-day symptomatic treatment for Alzheimer's disease. As no head to head study was performed yet, the objective of this study was to describe the daily practice of oral galantamine and rivastigmine transdermal patch in a real life (...) population of a memory clinic of a suburban teaching hospital in The Netherlands.A randomized open label study in 84 ambulant Alzheimer's patients with at least 6 months follow-up and treated either with oral galantamine (group G) or rivastigmine transdermal patch (group R). Data collection included patients' demographic and disease variables. Adverse events were collected and, in case of interruption of the primary treatment, the alternative treatment was registered.Serious adverse events did not occur

2010 Tijdschrift voor gerontologie en geriatrie Controlled trial quality: uncertain

116. Dementia: assessment, management and support for people living with dementia and their carers

dementia subtypes Managing medicines for all dementia subtypes 1.5.1 For guidance on managing medicines (including covert administration), see the NICE guidelines on managing medicines for adults receiving social care in the community and managing medicines in care homes. Pharmacological management of Alzheimer's disease Pharmacological management of Alzheimer's disease 1.5.2 The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as monotherapies are recommended (...) as options for managing mild to moderate Alzheimer's disease under all of the conditions specified in 1.5.5 and 1.5.6. This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. 1.5.3 Memantine monotherapy is recommended as an option for managing Alzheimer's disease for people with: moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or or Dementia: assessment

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

118. Parkinson?s disease in adults

with a UK marketing authorisation for this indication. Donepezil, galantamine and rivastigmine patches did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information. [6] At the time of publication (July 2017), cholinesterase inhibitors

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

120. Cholinergic medication for antipsychotic-induced tardive dyskinesia. (PubMed)

Cholinergic medication for antipsychotic-induced tardive dyskinesia. Tardive dyskinesia (TD) remains a troublesome adverse effect of conventional antipsychotic (neuroleptic) medication. It has been proposed that TD could have a component of central cholinergic deficiency. Cholinergic drugs have been used to treat TD.To determine the effects of cholinergic drugs (arecoline, choline, deanol, lecithin, meclofenoxate, physostigmine, RS 86, tacrine, metoxytacrine, galantamine, ipidacrine, donepezil

2018 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>